Viatris (VTRS) Net Cash Flow Growth (1y) (2020 - 2026)
Viatris (VTRS) Net Cash Flow Growth (1y) (2020 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | 112.26% |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | -44.11% |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | 209.30% |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | -236.85% |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | 13,485.29% |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | -1,047.81% |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | -1,020.00% |
| 10 | Vireo Growth | 10.51 Bn | 10.36 Bn | 59.30 Mn | 383.33% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 13,485.29% |
| Dec 31, 2025 | 133.29% |
| Sep 30, 2025 | -55.43% |
| Jun 30, 2025 | -109.89% |
| Mar 31, 2025 | -90.20% |
| Dec 31, 2024 | -234.30% |
| Sep 30, 2024 | 37.35% |
| Jun 30, 2024 | -168.99% |
| Mar 31, 2024 | 104.61% |
| Dec 31, 2023 | -155.47% |
| Sep 30, 2023 | 14,625.53% |
| Jun 30, 2023 | 327.70% |
| Mar 31, 2023 | -1,302.88% |
| Dec 31, 2022 | 1,419.69% |
| Sep 30, 2022 | -105.23% |
| Jun 30, 2022 | 58.57% |
| Mar 31, 2022 | 525.85% |
| Dec 31, 2021 | -127.73% |
| Mar 31, 2021 | -112.18% |
| Dec 31, 2020 | 49.13% |